Login to Your Account



Paion Stock Surges on Japanese Phase II/III Remimazolam Data

By Cormac Sheridan
Staff Writer

Friday, November 15, 2013
Shares in Paion AG surged more than 40 percent Thursday on news that its fast-acting anesthetic remimazolam hit the primary endpoint of a Phase II/III trial conducted by its Japanese partner, Osaka-based Ono Pharmaceutical Co. Ltd., and demonstrated a better cardiovascular safety profile than a widely used control drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription